<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129389</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2003-02</org_study_id>
    <secondary_id>2005-003109-10</secondary_id>
    <nct_id>NCT00129389</nct_id>
  </id_info>
  <brief_title>FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients</brief_title>
  <official_title>Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, randomized, phase III trial. Patients will be stratified
      after breast surgery, as per investigational site; menopausal status; node negative
      diagnosis, as per sentinel-node technique versus lymphadenectomy; hormone receptor status
      (positive versus negative).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to:

        -  Fluorouracil, doxorubicin, and cyclophosphamide (FAC) x 6 (cycles): 5-fluorouracil 500
           mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 day 1, every 3 weeks, for 6
           cycles.

        -  FAC x 4 (cycles) â†’ Paclitaxel x 8 (cycles): 5-fluorouracil 500 mg/m2 + doxorubicin 50
           mg/m2 + cyclophosphamide 500 mg/m2 day 1, every 3 weeks, for 4 cycles, followed by 8
           administrations of weekly paclitaxel 100 mg/m2

      Premenopausal women with hormone receptor positive tumors must receive tamoxifen 20 mg daily
      for 5 years, after the end of chemotherapy.

      Postmenopausal women with hormone receptor positive tumors are allowed to receive aromatase
      inhibitors as initial adjuvant hormone therapy or after tamoxifen.

      All patients with breast conservative surgery must receive radiotherapy.

      Estimated 5-year disease-free survival in the control arm (FAC x 6) is expected to be 80%. It
      is expected that disease-free survival will increase by 5% in the experimental arm
      (FAC-paclitaxel). 906 patients per arm must be recruited, to detect this difference with an
      alpha error of 0.05 and 80% power. Assuming a 6% post-randomization drop-out rate, 960
      patients per arm are needed, 1920 in total.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2003</start_date>
  <completion_date type="Actual">October 1, 2013</completion_date>
  <primary_completion_date type="Actual">October 1, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS) Event</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Event</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS event is defined as the death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1925</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: FAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FAC-wP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Arm A: FAC Arm B: FAC-wP</description>
    <arm_group_label>Arm A: FAC</arm_group_label>
    <arm_group_label>Arm B: FAC-wP</arm_group_label>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Arm A: FAC Arm B: FAC-wP</description>
    <arm_group_label>Arm A: FAC</arm_group_label>
    <arm_group_label>Arm B: FAC-wP</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Arm A: FAC Arm B: FAC-wP</description>
    <arm_group_label>Arm A: FAC</arm_group_label>
    <arm_group_label>Arm B: FAC-wP</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Arm B: FAC-wP</description>
    <arm_group_label>Arm B: FAC-wP</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3).
             Tumors must be Human Epidermal Growth Factor Receptor 2 (HER2) negative. Patients must
             be free of disease in the axilla (node negative). If lymphadenectomy is done, at least
             10 nodes must be examined. If sentinel node technique is used, sentinel node must be
             free of disease. Patients must present at least one high risk criterion (St. Gallen,
             1998) as follows:

               -  Tumor size &gt; 2 cm; and/or

               -  ER and Progesterone Receptor (PgR) negative; and/or

               -  Histological grade 2-3; and/or

               -  Age &lt; 35 years old.

          -  Time window between surgery and study randomization must be less than 60 days.

          -  Surgery must consist of mastectomy or conservative surgery. Margins free of disease
             and ductal carcinoma in situ (DCIS) are required. Lobular carcinoma is not considered
             a positive margin.

          -  Patients must not present evidence of metastatic disease.

          -  Status of hormone receptors in primary tumor. Results must be available before the end
             of adjuvant chemotherapy.

          -  Status of HER2 in primary tumor, known before randomization. Patients with
             Immunohistochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescent
             in situ hybridization (FISH) is mandatory and result must be negative.

          -  Age &gt;= 18 and &lt;= 70 years old.

          -  Performance status (Karnofsky index) &gt;= 80.

          -  Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed,
             normal cardiac function must be confirmed by left ventricular ejection fraction
             (LVEF).

          -  Laboratory results (within 14 days prior to randomization):

               -  Hematology: neutrophils &gt;= 1.5 x 10^9/l; platelets &gt;= 100x 10^9/l; hemoglobin &gt;=
                  10 mg/dl;

               -  Hepatic function: total bilirubin &lt;= 1 upper normal limit (UNL); Aspartate
                  aminotransferase (AST) and Alanine aminotransferase (ALT) &lt;= 2.5 UNL; alkaline
                  phosphatase &lt;= 2.5 UNL. If values of AST and ALT &gt; 1.5 UNL are associated with
                  alkaline phosphatase &gt; 2.5 UNL, patient is not eligible.

               -  Renal function: creatinine &lt;= 175 mmol/l (2 mg/dl); creatinine clearance &gt;= 60
                  ml/min.

          -  Complete stage workup during the 12 weeks prior to randomization (mammograms are
             allowed within a 20 week time window). All patients must have a bilateral mammogram,
             thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain,
             and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is
             recommended for all patients. Other tests, as clinically indicated.

          -  Patients able to comply with treatment and study follow-up.

          -  Negative pregnancy test done in the 14 previous days to randomization.

        Exclusion Criteria:

          -  Prior systemic therapy for breast cancer.

          -  Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any
             malignancy.

          -  Prior radiotherapy for breast cancer.

          -  Bilateral invasive breast cancer.

          -  Pregnant or lactating women. Adequate contraceptive methods must be used during
             chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14
             previous days to randomization.

          -  Any T4 or N1-3 or M1 tumor.

          -  HER2 positive breast cancer (IHC 3+ or positive FISH result).

          -  Pre-existing grade &gt;=2 motor or sensorial neurotoxicity by the National Cancer
             Institute Common Toxicity Criteria (NCICTC) v-2.0.

          -  Any other serious medical pathology, such as congestive heart failure, unstable
             angina, history of myocardial infarction during the previous year, uncontrolled
             hypertension or high risk arrhythmias.

          -  History of neurological or psychiatric disorders, which could preclude the patients to
             free informed consent.

          -  Active uncontrolled infection.

          -  Active peptic ulcer; unstable diabetes mellitus.

          -  Previous or current history of neoplasms different from breast cancer, except for skin
             carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;
             lobular in situ carcinoma.

          -  Concomitant treatment with other investigational products. Participation in other
             clinical trials with a non-marketed drug in the 20 previous days before randomization.

          -  Concomitant treatment with other therapy for cancer.

          -  Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Univ. De Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>3600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>8243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del EspÃ­ritu Santo</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>8923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Jerez de la Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>Cadiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de CastellÃ³n</name>
      <address>
        <city>CastellÃ³n De La Plana</city>
        <state>CastellÃ³n</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n Hospital de AlcorcÃ³n</name>
      <address>
        <city>AlcorcÃ³n</city>
        <state>MAdrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid- MonteprÃ­ncipe</name>
      <address>
        <city>Boadilla Del Monte</city>
        <state>Madrid</state>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de MÃ³stoles</name>
      <address>
        <city>MÃ³stoles</city>
        <state>MAdrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital PoliclÃ­nico Vigo POVISA</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Juan Canalejo</name>
      <address>
        <city>A CoruÃ±a</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro OncolÃ³gico de Galicia</name>
      <address>
        <city>A CoruÃ±a</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>2066</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de los Lirios</name>
      <address>
        <city>Alicante</city>
        <zip>3804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClÃ­nica Corochan S.A.</name>
      <address>
        <city>Barcelona</city>
        <zip>8017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Vic</name>
      <address>
        <city>Barcelona</city>
        <zip>8500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General YagÃ¼e</name>
      <address>
        <city>Burgos</city>
        <zip>9005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Luz</name>
      <address>
        <city>Cuenca</city>
        <zip>16002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina SofÃ­a</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Hospital Universitari Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de JaÃ©n</name>
      <address>
        <city>JaÃ©n</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Calde</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital RamÃ³n y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>MAdrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIOCC Hospital Norte-Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Virgen de la Victoria</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sta MarÃ­a Nai</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General RÃ­o CarriÃ³n</name>
      <address>
        <city>Palencia</city>
        <zip>34005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto OncolÃ³gico de Guipuzcoa</name>
      <address>
        <city>San SebastiÃ¡n</city>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San SebastiÃ¡n</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario MarquÃ©s de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Virgen del RocÃ­o</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de OncologÃ­a</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <zip>1009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 10, 2005</study_first_submitted>
  <study_first_submitted_qc>August 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Node negative, high risk breast cancer.</keyword>
  <keyword>Prognostic gene profile.</keyword>
  <keyword>Saint Gallen high risk criteria.</keyword>
  <keyword>Weekly paclitaxel.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1925 patients from 67 Spanish sites were assigned to receive FAC-wP (n=951) or FAC (n=974). 8 patients received no treatment (5 FAC-wP, 3 FAC), and 17 were not treated with the study medication to which they were randomly assigned (1 FAC, 16 FAC-wP). A total of 1,917 patients were evaluable for safety (931 FAC-wP, 986 FAC).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: FAC</title>
          <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: FAC-wP</title>
          <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="974"/>
                <participants group_id="P2" count="951"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="941">1 patient was crossed from arm A to B by error. 16 patients were crossed from arm B, to A by error.</participants>
                <participants group_id="P2" count="811">16 patients were crossed from arm B to A by error. 1 patient was crossed from arm A to B by error.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Crossed to the other arm</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: FAC</title>
          <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: FAC-wP</title>
          <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="974"/>
            <count group_id="B2" value="951"/>
            <count group_id="B3" value="1925"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.95" lower_limit="24" upper_limit="75"/>
                    <measurement group_id="B2" value="50.89" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="B3" value="50.92" lower_limit="24" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="974"/>
                    <measurement group_id="B2" value="951"/>
                    <measurement group_id="B3" value="1925"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="960"/>
                    <measurement group_id="B2" value="935"/>
                    <measurement group_id="B3" value="1895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (PS)</title>
          <description>The Karnofsky PS Index classify patients as to their functional impairment. The lower the Karnofsky score, the worse the survival.
100 to 80: Able to carry on normal activity and to work; no special care needed.
70 to 50: Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.
40 to 0: Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PS 80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS 90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS 100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="873"/>
                    <measurement group_id="B2" value="863"/>
                    <measurement group_id="B3" value="1736"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                    <measurement group_id="B2" value="482"/>
                    <measurement group_id="B3" value="954"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Peri/postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                    <measurement group_id="B2" value="469"/>
                    <measurement group_id="B3" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size</title>
          <description>Tumor (T) size describes the size of the tumour. Larger T is associated with inferior survival.
TX: can't be assessed. Tis: ductal carcinoma in situ. T1: tumour is 2 centimetres (cm) across or less. T1mi: tumour is 0.1cm across or less T1a: tumour &gt;0.1 cm but &lt;0.5 cm T1b: tumour &gt;0.5 cm but &lt;1 cm T1c: tumour &gt;1 cm but &lt;2 cm T2: tumour &gt;2 cm but &lt;5 cm across. T3: tumour &gt;5 cm across. T4a: tumour has spread into the chest wall T4b: tumour has spread into the skin and the breast might be swollen T4c: tumour has spread to both the skin and the chest wall T4d: inflammatory carcinoma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>T1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="557"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="1126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="772"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Invasive Ductal Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="832"/>
                    <measurement group_id="B2" value="813"/>
                    <measurement group_id="B3" value="1645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive Lobular Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic grade</title>
          <description>Cancer cells are given a Grade (G) when they are removed from the breast and checked under a microscope. The G is based on how much the cancer cells look like normal cells.
G1 or well differentiated (score 3, 4, or 5): cells are slower-growing, and look more like normal breast tissue.
G2 or moderately differentiated (score 6, 7): cells are growing at a speed of and look like cells somewhere between G1 and 3.
G3 or poorly differentiated (score 8, 9): cells look very different from normal and will probably grow and spread faster.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>GX: Differenciation cannot be assessed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G1: Well differenciated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G2: Moderately differenciated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="880"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G3: Poorly differenciated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="429"/>
                    <measurement group_id="B2" value="420"/>
                    <measurement group_id="B3" value="849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormonal receptors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ER positive and/or PR positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="713"/>
                    <measurement group_id="B2" value="693"/>
                    <measurement group_id="B3" value="1406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ER negative and/or PR negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Epidermal growth factor Receptor 2 (HER2) status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HER2 positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HER2 negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="858"/>
                    <measurement group_id="B2" value="846"/>
                    <measurement group_id="B3" value="1704"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triple-negative disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Triple-negative disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non triple-negative disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="735"/>
                    <measurement group_id="B2" value="708"/>
                    <measurement group_id="B3" value="1443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mastectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="526"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Conservative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="713"/>
                    <measurement group_id="B2" value="686"/>
                    <measurement group_id="B3" value="1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lymphadenectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="559"/>
                    <measurement group_id="B2" value="551"/>
                    <measurement group_id="B3" value="1110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sentinel node biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="384"/>
                    <measurement group_id="B3" value="786"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lymphadenectomy + Sentinel node biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS) Event</title>
        <description>DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: FAC</title>
            <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: FAC-wP</title>
            <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS) Event</title>
          <description>DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="951"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Event</title>
        <description>OS event is defined as the death from any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: FAC</title>
            <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: FAC-wP</title>
            <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Event</title>
          <description>OS event is defined as the death from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
                <count group_id="O2" value="951"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment up to 30 days after last study dose; All-Cause Mortality was assessed up to 5 years.</time_frame>
      <desc>Only Adverse Events grade 3 and 4 were collected. All Serious Adverse Events (SAEs) grade 1, 2, 3, 4 and 5 were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: FAC</title>
          <description>FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: FAC-wP</title>
          <description>FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v. 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <description>Grade 4 and Fever grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Bradycardia and dyspnea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Fistula-rectal/anal</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - appendicitis surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic - Hepatitis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>SGOT (AST) and SGPT (ALT)</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with grade 3 or 4 neutropenia</sub_title>
                <description>Grade 3 or 4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Wound-infectious</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - Right Essential Coxoartrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis, refractory septic shock</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI-CTCAE v. 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="442" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="523" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>BILIRUBIN</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cardiac Function</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cardiac Left Ventricular</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>SYNCOPE (FAINTING)</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>VASOVAGAL EPISODE</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>STOMATITIS/PHARYNGITIS (ORAL/PHARYNGEAL MUCOSITIS)</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA/HEARTBURN</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>GGT</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION/HYPERSENSITIVITY</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NEUTROPENIA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS/PULMONARY INFILTRATES</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurophaty-sensory</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION-ANXIETY, AGITATION</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Menses</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>HOT FLASHES/FLUSHES</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>PULMONARY</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>HAND FOOT SKIN REACTION</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="951"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="974"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="951"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

